Sharemaestro Newsreel

HC Wainwright Has Negative View of Talphera FY2029 Earnings

HC Wainwright has lowered its FY2029 earnings per share estimate for Talphera (NASDAQ:TLPH) to $0.12 from $0.13, while reiterating a "Buy" rating and a $3.00 price target. The firm also projected FY2030 EPS at $0.32. Talphera's stock has a "Hold" consensus rating from analysts, …

Crinetics Pharmaceuticals merger with Vertex Pharmaceuticals advances after regulatory clearances

The proposed merger between Crinetics Pharmaceuticals (NASDAQ:CRNX) and Vertex Pharmaceuticals (NASDAQ:VRTX) has progressed after securing regulatory clearances, including the expiration of the Hart-Scott-Rodino Antitrust Improvements Act waiting period and approvals in Austria, Germany, and Australia. The acquisition, valued at approximately $10 billion, is expected …

Kura Oncology FY2029 EPS Cut by Brookline Capital Markets

Equities Analysts Offer Predictions for MNPR FY2029 Earnings

Equities Analysts Offer Predictions for CADL FY2028 Earnings

HC Wainwright Has Bullish Estimate for ACRV FY2030 Earnings

Attention Long-Term Shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY); Bloom Energy Corporation (NYSE: BE); Erasca, Inc. (NASDAQ: ERAS); and Insulet Corporation (NASDAQ: PODD): Grabar Law Office is Investigating Claims on Your Behalf

Grabar Law Office is investigating potential breaches of fiduciary duty by officers and directors of ARS Pharmaceuticals, Inc., Bloom Energy Corporation, Erasca, Inc., and Insulet Corporation. The investigations concern various allegations including misleading statements regarding product timelines, supply chain reliance, and manufacturing issues, which …

RIGL Maintained by HC Wainwright & Co. -- Price Target Raised to $85

HC Wainwright & Co. maintained a "Buy" rating for Rigel Pharmaceuticals (RIGL), increasing its price target from $57.00 to $85.00, reflecting confidence in the company's future growth. Despite this, Rigel Pharmaceuticals is currently priced at $42.10, which is 56.7% overvalued compared to its GF …

Canton Strategic's locking-as-a-service offering generated about $1.3M

Canton Strategic Holdings, Inc. Releases Second Quarter 2026 Financial and Operational Results

Form 8K Lantern Pharma Inc For: 14 August By Investing.com

This article reports on the filing of a Form 8K by Lantern Pharma Inc. on August 14th. It is a brief announcement indicating a regulatory filing, without providing further details about the content of the 8K. The article is from Investing.com and is dated …

Form 8K TuHURA Biosciences Inc For: 14 August By Investing.com

This article reports that TuHURA Biosciences Inc. filed a Form 8K on August 14. The filing is a standard regulatory disclosure and contains no further details within this brief report, beyond mentioning the company's stock symbol, HURA, which was up 7.39% at the time …

Capricor Therapeutics (CAPR) Stock Surges on FDA Application Amendment Plans

Outlook Therapeutics (OTLK) Q3 Earnings Miss Highlight Valuation Challenges

Is Galectin Therapeutics Inc (GALT) Overvalued After Q2 Earnings Miss? GF Score: 22/100

Capricor Therapeutics (CAPR) Stock Surges on FDA Application Ame

Stifel reiterates Buy rating on Oculis stock, $40 target

Stifel has reiterated a Buy rating and a $40 price target for Oculis Holding AG (NASDAQ:OCS), based on discussions about its lead asset, privosegtor. Despite a recent stock drop and an "overvalued" assessment by InvestingPro, analysts maintain a strong buy consensus. Oculis is shifting …

Brokers Offer Predictions for RAPP Q1 Earnings

HC Wainwright Issues Pessimistic Outlook for UTHR Earnings

Noble Financial Has Pessimistic View of UNCY Q2 Earnings

HC Wainwright Has Negative Estimate for Erasca Q3 Earnings

PDS Biotechnology shareholders approve charter amendment and director elections

PDS Biotechnology Corporation shareholders have approved an amendment to the company's certificate of incorporation, increasing the number of authorized common shares from 150 million to 300 million. They also elected two Class B directors, Kamil Ali-Jackson and Ilian Iliev, and ratified KPMG US LLP …

Research Analysts Issue Forecasts for BCRX Q4 Earnings

Omeros: YARTEMLEA Is Off To A Blistering Start (NASDAQ:OMER)

Omeros Corporation has received a Buy rating due to YARTEMLEA's unexpectedly strong launch, generating $28.5 million in net sales and positive operating cash flow in its first full quarter. The drug's adoption is rapidly increasing across transplant centers, with high formulary approval rates and …

Natera (NTRA) Stock Looks Reasonable On Cash Flow But Rich On Sales

Vivos to discuss collaborations’ anticipated effect on revenue growth and cash burn

Vivos Therapeutics (NASDAQ: VVOS) will release its second quarter 2026 financial results after market close on Friday, August 14, 2026, and will host a conference call at 5:00 p.m. Eastern Time. Management plans to discuss strategic collaborations and their anticipated effect on near-term revenue …

Why is Alpha Cognition stock surging today?

Ultragenyx (RARE): RTW Investments and Roderick Wong report 7.9% stake

RTW Investments, LP and Roderick Wong, M.D. have reported a beneficial ownership of 7.9% in Ultragenyx Pharmaceutical Inc., totaling 7,796,895 shares. This disclosure, made via a Schedule 13G filing, indicates shared voting and dispositive power over these shares, which are held by funds advised …

HC Wainwright Analysts Boost Earnings Estimates for LifeMD

HC Wainwright analysts have increased their Q4 2027 earnings per share forecast for LifeMD to $0.17 from $0.15, while maintaining a "Buy" rating and a $9 price target. Despite this, analyst sentiment remains mixed with a "Moderate Buy" consensus rating but several recent downgrades. …

Earnings Release: Here's Why Analysts Cut Their LENZ Therapeutics, Inc. (NASDAQ:LENZ) Price Target To US$26.83

Analysts have revised down their revenue estimates for LENZ Therapeutics, Inc. for 2026 to US$17.0m, a significant 21% decline, despite beating recent revenue estimates. Although loss estimates were reduced, the consensus price target for LENZ Therapeutics was cut by 16% to US$26.83, reflecting pessimism …

Twist Bioscience (TWST): EdgePoint discloses 4.21% beneficial stake in amended 13G

EdgePoint Investment Group Inc. has filed an amended Schedule 13G, disclosing a 4.21% beneficial ownership stake in Twist Bioscience Corp (TWST), totaling 2,521,635 shares as of June 30, 2026. The filing indicates EdgePoint acts as an investment manager for various funds that directly own …

Sirenia Capital (TNXP) discloses 4.9% Tonix Pharmaceuticals stake including warrants

Sirenia Capital Management LP and Alex Silverstein have reported a beneficial ownership of 4.9% in Tonix Pharmaceuticals Holding Corp., which includes 814,801 shares of common stock. This stake comprises 615,025 shares issuable upon the exercise of warrants. The ownership percentage is calculated based on …

FDA approves Lantheus’ tau imaging agent for Alzheimer’s disease

The FDA has approved Lantheus Holdings Inc.'s TAUKLARIFY (florquinitau F 18 injection), a tau imaging agent for Alzheimer's disease. This radiodiagnostic agent is intended for brain PET scans in adults with cognitive impairment to identify tau neurofibrillary tangle pathology. The approval is based on …

Analyst Estimates: Here's What Brokers Think Of BridgeBio Pharma, Inc. (NASDAQ:BBIO) After Its Second-Quarter Report

This article analyzes what brokers think of BridgeBio Pharma, Inc. (NASDAQ:BBIO) following its second-quarter report. It would likely detail analyst ratings, price targets, and any changes in sentiment post-earnings, providing insights into the company's financial performance and future outlook from an investment perspective.

Q3 Earnings Estimate for AptarGroup Issued By Zacks Research

Q3 EPS Estimates for Journey Medical Cut by HC Wainwright